RIL
IKT icon

Rothschild Investment LLC’s Inhibikase Therapeutics IKT Stock Holding History

Rothschild Investment LLC’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$885 Buy
436
+408
+1,457% +$730 ﹤0.01% 3090
2026
Q1 		$47 Buy
+28
New +$50 ﹤0.01% 3467

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rothschild Investment LLC's IKT Position: Q2 2026 in Review

Rothschild Investment LLC increased its Inhibikase Therapeutics (IKT) stake by 1,457% in Q2 2026, buying an estimated $730 and bringing the position to 436 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Rothschild Investment LLC first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Rothschild Investment LLC held 436 shares of Inhibikase Therapeutics worth $885 as of Q2 2026.
  • Rothschild Investment LLC bought 408 Inhibikase Therapeutics shares in Q2 2026, an estimated $730.
  • Inhibikase Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3090 holding.
  • Rothschild Investment LLC first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.